运动功能和干预措施,以改善心力衰竭患者的脆弱性
Takuya Umehara1, Akinori Kaneguchi1, Nobuhisa Katayama2
1Department of Rehabilitation, Faculty of Rehabilitation, Hiroshima International University, Kurose-Gakuendai 555-36, Higashi-Hiroshima, Hiroshima, Japan.
The National medical journal of India
|April 21, 2025
概括
改善心力衰竭患者的脆弱性需要具体的干预措施. 早期有氧运动,在7天内开始,对于那些低静止心率的人来说,与药物治疗一起,显示出更好的结果的希望.
科学领域:
- 老年学是一门学科.
- 心脏病学 心脏病学
- 康复医学 康复医学 康复医学
背景情况:
- 关于影响心力衰竭患者虚弱改善的因素的研究有限.
- 运动治疗在一般心力衰竭患者群体中的有效性需要进一步研究.
研究的目的:
- 在住院期间识别影响老年心力衰竭患者虚弱改善的因素和干预措施.
- 评估特定治疗策略的有效性,以提高这个群体的身体功能.
主要方法:
- 一项多中心前性队列研究,涉及住院的心力衰竭患者.
- 考克斯回归分析以确定脆弱性改善的显著预测因素.
- 接收机运行特征 (ROC) 曲线分析,以确定关键预测指标的截止点.
主要成果:
- 高短物理性能电池 (SPPB) 椅子支架测试值和手握强度与脆弱性改善有关.
- 关键干预措施包括多巴胺的使用,低静止心率,早期启动有氧运动 (7天内),以及轻到高强度的有氧运动.
- 确定的截止值:SPPB椅子站测试 (2分),手握力 (13.7公斤),静止心率 (80次/分钟),运动开始 (7天),以及运动强度 (31.6%).
结论:
- 药物治疗和运动干预措施有效改善心力衰竭患者的虚弱.
- 早期有氧运动,在7天内开始,对于老年心力衰竭患者和低静止心率患者尤其有益.
- 考虑患者入院时的病情的个性化治疗方法对于优化虚弱改善至关重要.
更多相关视频
相关概念视频
01:26Heart Failure Drugs: Inotropic Agents
405
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
405
01:17Pathophysiology of Heart Failure
1.4K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.4K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
305
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
305
01:22Heart Failure Drugs: β-Blockers
260
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
260
01:22Heart Failure Drugs: Diuretics
282
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
282
01:23Imbalances in Cardiac Output
1.2K
The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to...
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to...
1.2K